Business Context and Reporting Period
Company: enVVeno Medical Corp (NVNO)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: A medical device company developing bioprosthetic solutions for Chronic Venous Insufficiency (CVI). The company previously received a "not-approvable" letter for its surgical VenoValve in August 2025 and has shifted focus to the enVVe System, a non-surgical, transcatheter replacement venous valve.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,849) | $(4,503) |
| Loss Per Share (Basic/Diluted) | $(5.89) | $(7.75) |
| Operating Expenses | $(4,062) | $(4,954) |
| Cash and Cash Equivalents | $2,597 | $2,937 |
| Short-term Investments | $22,333 | $25,147 |
| Total Cash & Investments | $24,930 | $28,084 |
| Working Capital | $23,346 | $26,704 |
| Net Cash Used in Operating Activities | $(3,238) | $(4,018) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $0.7 million (15%) to $3.8 million, driven primarily by a $0.9 million reduction in operating expenses.
- Operating Expenses: Total operating expenses declined $0.9 million. Research and Development (R&D) expenses fell 17% to $2.1 million due to reduced follow-up costs for the VenoValve study. Selling, General, and Administrative (SG&A) expenses fell 19% to $2.0 million, largely due to lower stock-based compensation.
- Other Income: Total other income decreased 53% to $0.2 million, primarily due to lower interest income and realized gains from trading securities compared to the prior year.
- Capital Structure: The company executed a 1-for-35 reverse stock split effective January 20, 2026. All share data in the filing has been retroactively adjusted.
Guidance, Outlook, and Risks
- Clinical Milestone: On April 29, 2026 (subsequent to period end), the FDA approved the Investigational Device Exemption (IDE) for the enVVe System. The pivotal TAVVE study is expected to commence later in 2026, starting with a 10-patient safety cohort followed by a 220-patient randomized study.
- Liquidity Outlook: Management estimates a cash burn rate of $3 million to $4 million per quarter currently, anticipating an increase to $4 million to $5 million per quarter in 2026. With $24.9 million in cash and investments as of March 31, 2026, the company projects sufficient capital to fund operations into the third quarter of 2027.
- Capital Needs: The company will need to raise additional capital in the future. In April 2026, it raised approximately $0.1 million via an at-the-market offering. Approximately $48.8 million remains available under the current program.
- Risks: No assurance exists that the enVVe System will receive FDA pre-market approval. The company has no approved products and no revenue. Failure to secure additional financing would have a material adverse effect on operations.
Investor Verification Checklist
- Regulatory Status: Verify the commencement date of the TAVVE pivotal study and the timeline for the 10-patient safety cohort results.
- Cash Runway: Monitor the actual quarterly cash burn rate against the projected $4M-$5M range to validate the Q3 2027 liquidity runway.
- Capital Raising: Track the utilization of the remaining $48.8 million at-the-market equity program and any new financing announcements.
- Expense Management: Confirm if the reduction in R&D expenses is sustainable or if costs will spike as the enVVe pivotal study enrollment begins.
- Stock Split Impact: Ensure all historical share data and per-share metrics are correctly adjusted for the 1:35 reverse stock split.